• 1
    Schneider R, Passo MH. Juvenile rheumatoid arthritis. Rheum Dis Clin North Am 2002: 28: 50330.
  • 2
    Silverman ED, Miller JJ III, Bernstein B, Shafai T. Consumption coagulopathy associated with systemic juvenile rheumatoid arthritis. J Pediatr 1983; 103: 8726.
  • 3
    De Vere-Tyndall A, Macauley D, Ansell BM. Disseminated intravascular coagulation complicating systemic juvenile chronic arthritis (“Still's disease”). Clin Rheumatol 1983; 2: 4158.
  • 4
    Scott PJ, Gerber P, Maryjowski MC, Pachman LM. Evidence for intravascular coagulation in systemic onset, but not polyarticular, juvenile rheumatoid arthritis. Arthritis Rheum 1985; 28: 25661.
  • 5
    Hadchouel M, Prieur AM, Griscelli C. Acute hemorrhagic, hepatic, and neurologic manifestations in juvenile rheumatoid arthritis: possible relationship to drugs or infection. J Pediatr 1985; 106: 5616.
  • 6
    Stephan JL, Zeller J, Hubert P, Herbelin C, Dayer JM, Prieur AM. Macrophage activation syndrome and rheumatic disease in childhood: a report of four new cases. Clin Exp Rheumatol 1993; 11: 4516.
  • 7
    Davies SV, Dean JD, Wardrop CA, Jones JH. Epstein-Barr virus-associated haemophagocytic syndrome in a patient with juvenile chronic arthritis. Br J Rheumatol 1994; 33: 4957.
  • 8
    Fishman D, Rooney M, Woo P. Successful management of reactive haemophagocytic syndrome in systemic-onset juvenile chronic arthritis [letter]. Br J Rheumatol 1995; 34: 888.
  • 9
    Mouy R, Stephan JL, Pillet P, Haddad E, Hubert P, Prieur AM. Efficacy of cyclosporine A in the treatment of macrophage activation syndrome in juvenile arthritis: report of five cases. J Pediatr 1996; 129: 7504.
  • 10
    Ravelli A, De Benedetti F, Viola S, Martini A. Macrophage activation syndrome in systemic juvenile rheumatoid arthritis successfully treated with cyclosporine. J Pediatr 1996; 128: 2758.
  • 11
    Quesnel B, Catteau B, Aznar V, Bauters F, Fenaux P. Successful treatment of juvenile rheumatoid arthritis associated haemophagocytic syndrome by cyclosporin A with transient exacerbation by conventional-dose G-CSF. Br J Haematol 1997; 97: 50810.
  • 12
    Prahalad S, Bove K, Dickens D, Lovell DJ, Grom AA. Etanercept in the treatment of macrophage activation syndrome. J Rheumatol 2001; 28: 21204.
  • 13
    Sawhney S, Woo P, Murray KJ. Macrophage activation syndrome: a potentially fatal complication of rheumatic disorders. Arch Dis Child 2001; 85: 4216.
  • 14
    Stephan JL, Kone-Paut I, Galambrun C, Mouy R, Bader-Meunier B, Prieur AM. Reactive haemophagocytic syndrome in children with inflammatory disorders: a retrospective study of 24 patients. Rheumatology (Oxford) 2001: 40: 128592.
  • 15
    Grom AA, Villanueva J, Lee S, Goldmuntz EA, Passo MH, Filipovich A. Natural killer cell dysfunction in patients with systemic-onset juvenile rheumatoid arthritis and macrophage activation syndrome. J Pediatr 2003; 142: 2926.
  • 16
    Wulffraat NM, Rijkers GT, Elst E, Brooimans R, Kuis W. Reduced perforin expression in systemic juvenile idiopathic arthritis is restored by autologous stem-cell transplantation. Rheumatology (Oxford) 2003; 42: 3759.
  • 17
    Wouters CH, Ceuppens JL, Stevens EA. Different circulating lymphocyte profiles in patients with different subtypes of juvenile idiopathic arthritis. Clin Exp Rheumatol 2002; 20: 23948.
  • 18
    Villanueva JL, Yang L, Graham BT, Filipovich AH, Grom AA. The extent of NK dysfunction in patients with systemic onset juvenile rheumatoid arthritis and macrophage activation syndrome [abstract]. Clin Exp Rheumatol 2003; 21: 546.
  • 19
    Lonceint J, Sassolas B, Lefur JM, Guillet G, Leroy JP. Panniculitis and macrophage activation syndrome in a child with lupus erythematosus. Ann Dermatol Venereol 2001; 128: 133942.
  • 20
    Reiner AP, Spivak JL. Hematophagic histiocytosis: a report of 23 new patients and a review of the literature. Medicine (Baltimore) 1988; 67: 36988.
  • 21
    Athreya BH. Is macrophage activation syndrome a new entity? Clin Exp Rheumatol 2002; 20: 1213.
  • 22
    Ramanan AV, Baildam EM. Macrophage activation syndrome is hemophagocytic lymphohistiocytosis: need for the right terminology [letter]. J Rheumatol 2002; 29: 1105.
  • 23
    Favara BE, Feller AC, Pauli M, Jaffe ES, Weiss LM, Arico M, et al. Contemporary classification of histiocytic disorders. The WHO Committee On Histiocytic/Reticulum Cell Proliferations. Reclassification Working Group of the Histiocyte Society. Med Pediatr Oncol 1997; 29: 15766.
  • 24
    Filipovich HA. Hemophagocytic lymphohistiocytosis. Immunol Allergy Clin North Am 2002; 22: 281300.
  • 25
    Clementi R, Emmi L, Maccario R, Liotta F, Moretta L, Danesino C, et al. Adult onset and atypical presentation of hemophagocytic lymphohistiocytosis in siblings carrying PRF1 mutations. Blood 2002; 100: 22667.
  • 26
    Bloom BJ, Tucker LB, Miller LC, Schaller JG. Fibrin D-dimer as a marker of disease activity in systemic onset juvenile rheumatoid arthritis. J Rheumatol 1998; 25: 16205.
  • 27
    Ravelli A. Macrophage activation syndrome. Curr Opin Rheumatol 2002; 14: 54852.
  • 28
    Emmenegger U, Reimers A, Frey U, Fux Ch, Bihl F, Semela D, et al. Reactive macrophage activation syndrome: a simple screening strategy and its potential in early treatment. Swiss Med Wkly 2002; 132: 2306.
  • 29
    Jacobs JC, Gorin LJ, Hanissian AS, Simon JL, Smithwick EM, Sullivan D. Consumption coagulopathy associated with gold therapy for JRA. J Pediatr 1984; 105: 6745.
  • 30
    Ravelli A, Caria MC, Buratti S, Malattia C, Temporini F, Martini A. Methotrexate as a possible trigger of macrophage activation syndrome in systemic juvenile idiopathic arthritis. J Rheumatol 2001; 28: 8657.
  • 31
    Eraso R, Gedalia A, Espinoza LR. Methotrexate as a possible trigger of macrophage activation syndrome in systemic juvenile idiopathic arthritis. J Rheumatol 2002; 29: 11045.
  • 32
    Lau G, Kwan C, Chong SM. The 3-week sulphasalazine syndrome strikes again. Forensic Sci Int 2001; 122: 7984.
  • 33
    Ramanan AV, Schneider R. Macrophage activation syndrome following initiation of etanercept in a child with systemic onset juvenile rheumatoid arthritis. J Rheumatol 2003; 30: 4013.
  • 34
    Lambotte O, Cacoub P, Costedoat N, Le Moel G, Amoura Z, Piette JC. High ferritin and low glycosylated ferritin may be a marker of excessive macrophage activation. J Rheumatol 2003; 30: 10278.
  • 35
    Van der Poll T, Buller HR, ten Cate H, Wortel CH, Bauer KA, van Deventer SJ, et al. Activation of coagulation after administration of TNF to normal subjects. N Engl J Med 1990; 322: 16227.
  • 36
    De Benedetti F, Pignatti P, Massa M, Sartirana P, Ravelli A, Cassani G, et al. Soluble tumour necrosis factor receptor levels reflect coagulation abnormalities in systemic juvenile chronic arthritis. Br J Rheumatol 1997; 36: 5818.
  • 37
    Imagawa T, Katakura S, Mori M, Aihara Y, Mitsuda T, Yokota S. A case of macrophage activation syndrome developed with systemic onset juvenile rheumatoid arthritis. Ryumachi 1997; 37: 48792.
  • 38
    Ramanan AV, Wynn RF, Kelsey A, Baildam EM. Systemic juvenile idiopathic arthritis, Kikuchi's disease and haemophagocytic lymphohistiocytosis: is there a link? Case report and literature review. Rheumatology (Oxford) 2003; 42: 5968.
  • 39
    Smith KJ, Skelton HG, Yeager, Angritt P, Wagner K, James WD, et al. Cutaneous, histopathologic, immunohistochemical, and clinical manifestations in patients with hemophagocytic syndrome. Military Medical Consortium for Applied Retroviral Research (MMCARR). Arch Dermatol 1992; 128: 193200.
  • 40
    Schuval SJ, Frances A, Valderrama E, Bonagura VR, Ilowite NT. Panniculitis and fever in children. J Pediatr 1993; 122: 3728.
  • 41
    Arico M, Danesino C, Pende D, Moretta L. Pathogenesis of haemophagocytic lymphohistiocytosis. Br J Haematol 2001; 114: 7619.
  • 42
    Egeler RM, Shapiro R, Loechelt B, Filipovich A. Characteristic immune abnormalities in hemophagocytic lymphohistiocytosis. J Pediatr Hematol Oncol 1996; 18: 3405.
  • 43
    Sullivan KE, Delaat CA, Douglas SD, Filipovich AH. Defective natural killer cell function in patients with hemophagocytic lymphohistiocytosis and in first degree relatives. Pediatr Res 1998; 44: 4658.
  • 44
    Stepp SE, Dufourcq-Lagelouse R, Le Deist F, Bhawan S, Certain S, Mathew P, et al. Perforin gene defects in familial hemophagocytic lymphohistiocytosis. Science 1999; 286: 19579.
  • 45
    Kogawa K, Lee SM, Villanueva J, Marmer D, Sumegi J, Filipovich AH. Perforin expression in cytotoxic lymphocytes from patients with hemophagocytic lymphohistiocytosis and their family members. Blood 2002; 99: 616.
  • 46
    Barbosa MD, Nguyen QA, Tchernev VT, Ashley JA, Detter JC, Blaydes SM, et al. Identification of the homologous beige and Chediak-Higashi syndrome genes. Nature 1996; 382: 2625.
  • 47
    Baetz K, Isaaz S, Griffiths GM. Loss of cytotoxic T lymphocyte function in Chediak-Higashi syndrome arises from a secretory defect that prevents lytic granule exocytosis. J Immunol 1995; 154: 612233.
  • 48
    Menasche G, Pastural E, Feldmann J, Certain S, Ersoy F, Dupuis S, et al. Mutations in RAB27A cause Griscelli syndrome associated with haemophagocytic syndrome. Nat Genet 2000; 25: 1736.
  • 49
    Sayos J, Nguyen KB, Wu C, Stepp SE, Howie D, Schatzle JD, et al. Potential pathways for regulation of NK and T cell responses: differential X-linked lymphoproliferative syndrome gene product SAP interactions with SLAM and 2B4. Int Immunol 2000; 12: 174957.
  • 50
    Nakajima H, Cella M, Bouchon A, Grierson HL, Lewis J, Duckett CS, et al. Patients with X-linked lymphoproliferative disease have a defect in 2B4 receptor-mediated NK cell cytotoxicity. Eur J Immunol 2000; 30: 330918.
  • 51
    Arnaout RA. Perforin deficiency: fighting unarmed [letter]. Immunol Today 2000; 21: 592.
  • 52
    Matloubian M, Suresh M, Glass A, Galvan M, Chow K, Whitmire JK, et al. A role for perforin in downregulating T-cell responses during chronic viral infection. J Virol 1999; 73: 252736.
  • 53
    Su HC, Nguyen KB, Salazar-Mather TP, Ruzek MC, Dalod MY, Biron CA. NK functions restrain T cell responses during viral infections. Eur J Immunol 2001; 31: 304855.
  • 54
    Kagi D, Odermatt B, Mak TW. Homeostatic regulation of CD8+ T cells by perforin. Eur J Immunol 1999; 29: 326272.
  • 55
    Stepp SE, Mathew PA, Bennett M, de Saint Basile G, Kumar V. Perforin: more than just an effector molecule. Immunol Today 2000; 21: 2546.
  • 56
    Schreiber SL, Crabtree GR. The mechanism of action of cyclosporin A and FK506. Immunol Today 1992; 13: 13642.
  • 57
    Henter JI, Arico M, Egeler RM, Elinder G, Favara BE, Filipovich AH, et al. HLH-94: a treatment protocol for hemophagocytic lymphohistiocytosis. HLH Study Group of the Histiocyte Society. Med Pediatr Oncol 1997; 28: 3427.
  • 58
    Aeberli D, Oertle S, Mauron H, Reichenbach S, Jordi B, Villiger PM. Inhibition of TNF-pathway: use of infliximab and etanercept as remission-inducing agents in cases of therapy-resistant chronic inflammatory disorders. Swiss Med Wkly 2002; 132: 41422.
  • 59
    Janka GE. Familial hemophagocytic lymphohistiocytosis. Eur J Pediatr 1983; 140: 22130.